Neuroprotective effect of Vinpocetine against 3- NP Induced reduction of body weight and oxidative stress in Rats

doi: 10.5138/ijpm.v3i3.377

Abstract

Huntington’s disease is a progressive, degenerative disease characterized by abnormal body movements symptoms like chorea and a reduction of body weight . Recently, it has been reported that oxidative stress, which is one of the pathological hallmarks of various neurodegenerative disorders, also plays an important role in the pathogenesis of Huntington’s disease.  3- Nitropropionic acid , a neurotoxin  treatment significantly reduction in body weight.  Intraperitoneal administration of 3-nitropropionic acid (10 mg/kg  for 14 days) caused significant loss of body weight and poor rentention of memory. Biochemical analysis revealed that 3-NP administration significantly increase in lipid peroxidation in the brains of rats.  The present study demonstrated that inhibition of type 1 phosphodiesterase (PDE1) by vinpocetine    (5, 10 & 20mg\kg) significantly reversed behavioral and biochemical dysfunction in 3-NP treated group. The result of the present study suggests facilitatory role of PDE1 enzyme in loss in body weight and oxidative stress following 3-NP injection.

Vonsattel JP, DiFiglia M. Huntington disease, J. Neuropathol Exp Neurol 1998;57:369-384.

Martin JB. and Gusella JF. Huntington’s disease: pathogenesis and management. N Engl J. Med 1986; 315: 1267-1276.

Cruz, V and Santamaria, A. Integrative Hypothesis for Huntington’s disease: A Brief Review of Experimental Evidence. Physiol. Res 2007; 56: 513-526.

La Fontaine MA, Geddes JW, Banks A and Butterfield DA. Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid – induced in vivo oxidative stress and striatal lesions: insights into Huntington’s disease. J Neurochem 2000; 75: 1709- 1715.

Kumar P, Padi SSV, Naidu PS and Kumar A. Possible Neuroprotective of Curcumin in Attenuating 3-Nitropropionic Acid –Induced Neurotoxicity. Methods Find. Exp. Clin. Pharmacol 2006; 17: 485- 92.

KimYJ ,Yi ,Y Sapp, Wang Y, Cuiffo B, Kegel, Qin ZH, Aronin, DiFiglia M. Capase3- cleaved N- terminal fragments of wild type and mutant huntingtin are present in normal and Huntington’s disease brains , associate with membranes, undergo calpain – dependent proteolysis. Proc. Natl. Acad Sci . U.S.A. 2001; 98: 12784- 12789.

Vis JC, Van Huizen RT, Veerbeek MM, de Waal RM, ten Donkelaar HJ and Kremer B. Creatine protects against 3- nitropropionic acid-induced cell death in murine corticostriatal slice cultures. Brain Res 2004; 1024: 16-24.

Beal MF. Mitochondrial dysfunction in neurodegenerative disease. Biochem Biophy Acta 1998; 1366: 211-223.

Nagakura M, Oosumi K, Hirano H, Onishi Y. Pharmcogenomics and therapeutics trategies for Dementia . Science direct 2002; 34:357- 379.

Puzzo D, Vitolo O , Trinchese F, Joel P, Jacob AP, Arancio . Neurobiology of Disease Amyloid β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity. J Neuroscience 2005; 25: 6887– 6897.

Fujita SS, Zghb J, Hong . Species differences in Brain phosphodiesterase levels . J Neural Transm 2008; 41:185.

Nibuya M , Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365–2372.

Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inihibitor. Biochem Biophys Rest Commun 1999; 19 :20-24.

Song, Perides, Liu and YF .Expression of full length polyglutamine expanded Huntington distrupt growth factor receptor signaling in rat. J Biolchem 1997; 277:6703-6707.

Bishop VS, DM Farrell. The role of cGMP and cAMP in active thermoregulatory vasodilation. Neurobiol Dis 1997; 272: R975- R981.

O’Donnell JM and Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase. Trends Pharmacol. Sci 2004; 25: 158–163.

K Tarnok, E Kiss, PGM Luiten, C Nyakas, K Tihanyi, K Schlett ,and ULM Eisel. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Curr Pharm Des 2008; 66: 63- 65.

Lugnier C: Cyclic nucleotide phosphodiesterase superfamily. Pharmacol Ther 2006; 109:366-398.